As Biogen Idec (BIIB) Share Price Declined, Citizens & Northern Has Trimmed Stake by $475844 …

… CIA nominee; 26/04/2018 – Tesla Head of Autopilot Jim Keller Leaves to Join Intel; 23/05/2018 – C3 IoT Partners With Intel to Deliver AI Appliance; …

Intel Corporation (NASDAQ:INTC) Logo

Fairfield Bush & Company increased its stake in Intel Corporation (INTC) by 153.9% based on its latest 2018Q3 regulatory filing with the SEC. Fairfield Bush & Company bought 11,950 shares as the company’s stock rose 1.97% while stock markets declined. The institutional investor held 19,715 shares of the semiconductors company at the end of 2018Q3, valued at $932,000, up from 7,765 at the end of the previous reported quarter. Fairfield Bush & Company who had been investing in Intel Corporation for a number of months, seems to be bullish on the $224.50 billion market cap company. The stock increased 1.49% or $0.72 during the last trading session, reaching $49.19. About 29.87 million shares traded or 4.94% up from the average. Intel Corporation (NASDAQ:INTC) has risen 9.59% since January 20, 2018 and is uptrending. It has outperformed by 9.59% the S&P500. Some Historical INTC News: 05/03/2018 Sen. Rich Burr: ADVISORY: Senate Intel Committee to Hold Security Clearance Reform Hearing This Week; 13/03/2018 – Top Democrat on U.S. Senate Intel: ‘lot of questions’ about Trump CIA nominee; 26/04/2018 – Tesla Head of Autopilot Jim Keller Leaves to Join Intel; 23/05/2018 – C3 IoT Partners With Intel to Deliver AI Appliance; 02/04/2018 – DDN Named Datacenter Platform Partner of the Year at Intel Technology Partner Awards, Recognizing its Market Leadership at Scale; 22/05/2018 – Intel Finds Another Chip Exploit, Says Fix Is in Place (Correct); 10/04/2018 – Australian Gov: WIPO PUBLISHES PATENT OF INTEL FOR “TRANSISTORS WITH VERTICALLY OPPOSED SOURCE AND DRAIN METAL INTERCONNECT; 26/04/2018 – INTEL SEES 2Q REV. $16.3B +/- $500M, EST. $15.6B; 21/05/2018 – Micron and Intel Extend their Leadership in 3D NAND Flash memory; 11/04/2018 – New York Post: Justice Deptartment hands over document to House Intel panel

Citizens & Northern Corp decreased its stake in Biogen Idec Inc (BIIB) by 29.33% based on its latest 2018Q3 regulatory filing with the SEC. Citizens & Northern Corp sold 1,348 shares as the company’s stock declined 6.12% with the market. The institutional investor held 3,248 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $1.15M, down from 4,596 at the end of the previous reported quarter. Citizens & Northern Corp who had been investing in Biogen Idec Inc for a number of months, seems to be less bullish one the $67.98 billion market cap company. The stock decreased 0.27% or $0.92 during the last trading session, reaching $337.42. About 1.27 million shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 0.04% since January 20, 2018 and is downtrending. It has underperformed by 0.04% the S&P500. Some Historical BIIB News: 01/05/2018 – Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab; 23/04/2018 – BIOGEN: SHINE DATA ILLUSTRATES SPINRAZA’S LONGER-TERM BENEFITS; 12/03/2018 – Biogen Announces New Interim Phase 2 Results From NURTURE; 05/04/2018 – AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023; 05/03/2018 VP McKenzie Disposes 110 Of Biogen Inc; 25/05/2018 – Biogen’s Avonex Sales Rise; Multiple Sclerosis Market Up 1%; 12/03/2018 – BIOGEN: SPINRAZA TRIAL SHOWED IMPROVED MOTOR FUNCTION; 24/04/2018 – Biogen Idec 1Q Adj EPS $6.05; 20/04/2018 – BIOGEN – IN COLLABORATION BIOGEN WILL BE RESPONSIBLE FOR AND PAY FOR NON-CLINICAL STUDIES, CLINICAL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION; 27/03/2018 – ICCR: Shareholders Will Vote on Resolutions at AbbVie, Amgen, Biogen, Bristol-Myers Squibb and Eli Lilly

Among 35 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 27 have Buy rating, 0 Sell and 8 Hold. Therefore 77% are positive. Biogen Idec Inc. had 147 analyst reports since July 23, 2015 according to SRatingsIntel. On Monday, July 17 the stock rating was maintained by BMO Capital Markets with “Hold”. The rating was maintained by BMO Capital Markets on Thursday, January 25 with “Buy”. The rating was reinitiated by PiperJaffray on Monday, October 23 with “Overweight”. Citigroup upgraded Biogen Inc. (NASDAQ:BIIB) on Friday, July 6 to “Buy” rating. H.C. Wainwright initiated Biogen Inc. (NASDAQ:BIIB) rating on Tuesday, August 11. H.C. Wainwright has “Buy” rating and $380 target. The firm has “Hold” rating by Jefferies given on Tuesday, July 11. Goldman Sachs upgraded the shares of BIIB in report on Wednesday, August 16 to “Conviction Buy” rating. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Wednesday, April 25 by Robert W. Baird. Guggenheim maintained the stock with “Buy” rating in Friday, March 2 report. Robert W. Baird maintained the stock with “Neutral” rating in Wednesday, July 25 report.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 29 before the open. They expect $6.72 EPS, up 27.76% or $1.46 from last year’s $5.26 per share. BIIB’s profit will be $1.35B for 12.55 P/E if the $6.72 EPS becomes a reality. After $7.40 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -9.19% negative EPS growth.

Investors sentiment decreased to 1.01 in 2018 Q3. Its down 0.01, from 1.02 in 2018Q2. It is negative, as 45 investors sold BIIB shares while 334 reduced holdings. 138 funds opened positions while 243 raised stakes. 167.21 million shares or 1.69% less from 170.10 million shares in 2018Q2 were reported. Federated Pa invested in 225,093 shares or 0.19% of the stock. The Illinois-based First Trust Advisors LP has invested 0.22% in Biogen Inc. (NASDAQ:BIIB). Bluecrest Limited accumulated 21,022 shares or 0.2% of the stock. Osborne Prtnrs Capital Limited Liability Company holds 1,580 shares or 0.07% of its portfolio. Ami Asset Corporation owns 83,042 shares. Alliancebernstein Lp invested 0.72% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Hanson Mcclain Incorporated reported 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Corporation, a Missouri-based fund reported 865 shares. Eaton Vance Mgmt holds 0.35% in Biogen Inc. (NASDAQ:BIIB) or 448,641 shares. Apg Asset Mngmt Nv holds 0.34% or 635,530 shares in its portfolio. Neuberger Berman Gp holds 0.01% or 21,035 shares in its portfolio. Lpl Ltd Llc reported 0.04% of its portfolio in Biogen Inc. (NASDAQ:BIIB). 4.32M were accumulated by Fmr Limited Liability Company. Rmb Limited Liability Co accumulated 6,911 shares. Rhode Island-based Amica Retiree Medical Trust has invested 0.31% in Biogen Inc. (NASDAQ:BIIB).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Nasdaq.com which released: “Notable Friday Option Activity: BIIB, CMI, CSU – Nasdaq” on January 18, 2019, also Nasdaq.com with their article: “Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions – Nasdaq” published on January 04, 2019, Fool.com published: “Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes? – Motley Fool” on January 20, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Better Buy: Biogen vs. Gilead Sciences – Nasdaq” published on January 19, 2019 as well as Gurufocus.com‘s news article titled: “6 Stocks Beating the Market – GuruFocus.com” with publication date: January 17, 2019.

Since September 26, 2018, it had 0 insider buys, and 1 sale for $350,000 activity.

Among 57 analysts covering Intel Corporation (NASDAQ:INTC), 33 have Buy rating, 7 Sell and 17 Hold. Therefore 58% are positive. Intel Corporation had 303 analyst reports since August 7, 2015 according to SRatingsIntel. Needham maintained the shares of INTC in report on Friday, July 28 with “Buy” rating. Drexel Hamilton downgraded Intel Corporation (NASDAQ:INTC) on Friday, August 7 to “Hold” rating. The firm has “Neutral” rating given on Monday, September 19 by Citigroup. UBS maintained Intel Corporation (NASDAQ:INTC) rating on Wednesday, October 19. UBS has “Buy” rating and $40 target. The firm has “Buy” rating given on Thursday, January 25 by KeyBanc Capital Markets. The firm has “Buy” rating given on Wednesday, October 19 by B. Riley & Co. UBS downgraded it to “Neutral” rating and $34.0 target in Tuesday, January 5 report. The firm has “Buy” rating given on Tuesday, September 6 by Evercore. The stock of Intel Corporation (NASDAQ:INTC) earned “Buy” rating by Nomura on Friday, October 27. RBC Capital Markets maintained the shares of INTC in report on Friday, October 6 with “Hold” rating.

Fairfield Bush & Company, which manages about $437.54M and $356.26 million US Long portfolio, decreased its stake in Super Micro Computer Inc. (NASDAQ:SMCI) by 34,150 shares to 124,563 shares, valued at $2.57 million in 2018Q3, according to the filing. It also reduced its holding in Jpmorgan Chase & Co (NYSE:JPM) by 9,635 shares in the quarter, leaving it with 112,830 shares, and cut its stake in Taiwan Semiconductor (NYSE:TSM).

Investors sentiment increased to 0.85 in 2018 Q3. Its up 0.04, from 0.81 in 2018Q2. It improved, as 62 investors sold INTC shares while 728 reduced holdings. 113 funds opened positions while 557 raised stakes. 2.86 billion shares or 2.41% less from 2.93 billion shares in 2018Q2 were reported. Vision Cap Mgmt reported 4,841 shares. Capstone Inv Limited Liability reported 128,783 shares or 0.07% of all its holdings. Clifford Swan Inv Counsel Ltd Limited Liability Company, California-based fund reported 577,249 shares. Qs Limited Liability Corporation reported 0.16% stake. Psagot Investment House Ltd reported 0.07% in Intel Corporation (NASDAQ:INTC). Family Capital Tru holds 0.09% or 4,500 shares. Regentatlantic Cap Lc invested in 1.75% or 481,618 shares. Mcdaniel Terry And holds 544,173 shares. Systematic Financial Mngmt LP invested 0.14% in Intel Corporation (NASDAQ:INTC). Whitnell has invested 1.41% of its portfolio in Intel Corporation (NASDAQ:INTC). 24,741 were reported by Asset Management Of Georgia Ga Adv. Sirios Capital Mgmt Lp reported 741,462 shares. Heritage Wealth reported 7,526 shares or 0.07% of all its holdings. Murphy Inc, a New Jersey-based fund reported 31,716 shares. Wealthtrust stated it has 10,798 shares or 0.24% of all its holdings.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Nasdaq.com which released: “3 Intel Product Launches to Expect in 2019 – Nasdaq” on January 14, 2019, also Nasdaq.com with their article: “Weekly Market Preview: Five Stocks To Watch For the Coming Week (IBM, CMCSA, F, INTC, SBUX) – Nasdaq” published on January 20, 2019, Forbes.com published: “How Much Revenue And Earnings Could Intel Stand To Lose If Apple Deploys Its Own Chips For Mac? – Forbes” on December 21, 2018. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Nasdaq.com and their article: “Intel (INTC) Dips More Than Broader Markets: What You Should Know – Nasdaq” published on January 14, 2019 as well as Nasdaq.com‘s news article titled: “Should Value Investors Pick Intel Corporation (INTC) Stock? – Nasdaq” with publication date: January 07, 2019.

Since July 25, 2018, it had 2 insider purchases, and 7 insider sales for $723,730 activity. Shenoy Navin sold $226,100 worth of stock. SWAN ROBERT HOLMES had bought 5,117 shares worth $247,155. $295,945 worth of Intel Corporation (NASDAQ:INTC) was sold by McBride Kevin Thomas.

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Related Posts:

  • No Related Posts

Steward Partners Investment Advisory LLC Sells 144 Shares of Biogen Inc (BIIB)

Acadian Asset Management LLC lifted its position in shares of Biogen by 2,188.6% in the 3rd quarter. Acadian Asset Management LLC now owns …

Biogen logoSteward Partners Investment Advisory LLC cut its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 3.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,785 shares of the biotechnology company’s stock after selling 144 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Biogen were worth $1,138,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BIIB. National Asset Management Inc. lifted its position in shares of Biogen by 120.6% in the 3rd quarter. National Asset Management Inc. now owns 1,899 shares of the biotechnology company’s stock worth $672,000 after purchasing an additional 1,038 shares during the period. Acadian Asset Management LLC lifted its position in shares of Biogen by 2,188.6% in the 3rd quarter. Acadian Asset Management LLC now owns 122,418 shares of the biotechnology company’s stock worth $43,254,000 after purchasing an additional 117,069 shares during the period. Jackson Square Partners LLC lifted its position in shares of Biogen by 5.7% in the 3rd quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after purchasing an additional 121,072 shares during the period. Blair William & Co. IL lifted its position in shares of Biogen by 17.4% in the 3rd quarter. Blair William & Co. IL now owns 18,449 shares of the biotechnology company’s stock worth $6,518,000 after purchasing an additional 2,735 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its position in shares of Biogen by 13.0% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 321,622 shares of the biotechnology company’s stock worth $113,632,000 after purchasing an additional 37,049 shares during the period. Institutional investors and hedge funds own 86.77% of the company’s stock.

Shares of NASDAQ:BIIB opened at $337.42 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.46 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $67.98 billion, a P/E ratio of 15.47, a P/E/G ratio of 1.23 and a beta of 0.99. Biogen Inc has a fifty-two week low of $249.17 and a fifty-two week high of $388.67.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, October 23rd. The biotechnology company reported $7.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $6.78 by $0.62. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.33 billion. Biogen had a net margin of 24.08% and a return on equity of 38.70%. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm earned $6.31 EPS. On average, analysts expect that Biogen Inc will post 25.84 EPS for the current year.

Several analysts have recently weighed in on BIIB shares. BidaskClub upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Royal Bank of Canada lowered their price objective on shares of Biogen to $338.00 and set a “sector perform” rating for the company in a research note on Monday, November 26th. Oppenheimer lowered their price objective on shares of Biogen from $380.00 to $372.00 and set an “outperform” rating for the company in a research note on Tuesday, December 18th. ValuEngine lowered shares of Biogen from a “hold” rating to a “sell” rating in a research note on Wednesday, December 19th. Finally, BTIG Research started coverage on shares of Biogen in a research note on Thursday, December 20th. They issued a “buy” rating and a $362.00 price objective for the company. Eight analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $381.86.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.fairfieldcurrent.com/news/2019/01/20/steward-partners-investment-advisory-llc-sells-144-shares-of-biogen-inc-biib.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Featured Story: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding BIIB?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Acadian Asset Management Stake in Independent Bank Mich (IBCP) Has Increased by $366666 …

Acadian Asset Management Llc increased its stake in Independent Bank Corp Mich (IBCP) by 33.25% based on its latest 2018Q3 regulatory filing with …

Biogen Inc. (NASDAQ:BIIB) Logo

Acadian Asset Management Llc increased its stake in Independent Bank Corp Mich (IBCP) by 33.25% based on its latest 2018Q3 regulatory filing with the SEC. Acadian Asset Management Llc bought 15,942 shares as the company’s stock declined 13.72% with the market. The institutional investor held 63,883 shares of the major banks company at the end of 2018Q3, valued at $1.51M, up from 47,941 at the end of the previous reported quarter. Acadian Asset Management Llc who had been investing in Independent Bank Corp Mich for a number of months, seems to be bullish on the $552.50 million market cap company. The stock decreased 0.22% or $0.05 during the last trading session, reaching $22.92. About 130,273 shares traded or 4.63% up from the average. Independent Bank Corporation (NASDAQ:IBCP) has declined 7.15% since January 18, 2018 and is downtrending. It has underperformed by 7.15% the S&P500. Some Historical IBCP News: 20/04/2018 – DJ Independent Bank Corporation, Inst Holders, 1Q 2018 (IBCP); 15/03/2018 – INDEPENDENT BANK CORP – MERGER OF CO AND TCSB IS CURRENTLY EXPECTED TO BE EFFECTIVE ON APR. 1, 2018; 11/04/2018 – Idaho Independent Bank 1Q Net $1.43M; 24/04/2018 – Independent Bank Corporation Announces Appointment of Terry Beia to Its Board of Directors; 24/04/2018 – Independent Bank Corp: Terry Beia Appointed to Its Bd of Directors; 11/04/2018 – Idaho Independent Bank 1Q EPS 18c; 15/03/2018 Independent Bank Corporation Announces Shareholder Approval To Acquire Traverse City State Bank; 22/03/2018 – Independent Bank – Mich Closes Below 50-Day Average: Technicals; 02/04/2018 – Independent Bank Corporation Announces Completion Of Merger With TCSB Bancorp, Inc; 23/05/2018 – OTC Markets Group Welcomes Citizens Independent Bancorp to OTCQX

Montecito Bank & Trust decreased its stake in Biogen Inc (BIIB) by 51.05% based on its latest 2018Q3 regulatory filing with the SEC. Montecito Bank & Trust sold 896 shares as the company’s stock declined 6.12% with the market. The institutional investor held 859 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $303,000, down from 1,755 at the end of the previous reported quarter. Montecito Bank & Trust who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $68.17 billion market cap company. The stock increased 1.90% or $6.31 during the last trading session, reaching $338.34. About 12 shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 0.04% since January 18, 2018 and is downtrending. It has underperformed by 0.04% the S&P500. Some Historical BIIB News: 05/04/2018 – BIOGEN – UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE, ON A COUNTRY-BY-COUNTRY BASIS; 20/04/2018 – BIOGEN INC – UNDER TERMS OF COLLABORATION CO MAY PAY MILESTONE PAYMENTS, LICENSE FEES AND ROYALTIES ON NET SALES; 07/03/2018 – EMA- EMA RECOMMENDATION FOLLOWING 12 REPORTS OF SERIOUS INFLAMMATORY BRAIN DISORDERS WORLDWIDE, INCLUDING ENCEPHALITIS AND MENINGOENCEPHALITIS; 20/04/2018 – BIOGEN INC – IN COLLABORATION, IONIS WILL BE RESPONSIBLE FOR IDENTIFICATION OF ANTISENSE DRUG CANDIDATES BASED ON SELECTED TARGETS; 20/04/2018 – Biogen May Pay Milestone Payments, License Fees and Royalties on Net Sales; 30/04/2018 – M&G – Episode Growth Exits Biogen; 24/04/2018 – Biogen’s revenue misses as Spinraza sales disappoint; 13/04/2018 – Brightwire: Biogen likely to exercise option to raise stake in Samsung Bioepis, insiders say; 20/04/2018 – BIOGEN INC – WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF COLLABORATION AND WILL BE RESPONSIBLE FOR THEIR DEVELOPMENT AND COMMERCIALIZATION; 15/05/2018 – Bridgewater Adds Biogen, Exits Costco, Buys More Newfield: 13F

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 29 before the open. They expect $6.72 EPS, up 27.76% or $1.46 from last year’s $5.26 per share. BIIB’s profit will be $1.35 billion for 12.59 P/E if the $6.72 EPS becomes a reality. After $7.40 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -9.19% negative EPS growth.

Among 35 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 27 have Buy rating, 0 Sell and 8 Hold. Therefore 77% are positive. Biogen Idec Inc. had 147 analyst reports since July 23, 2015 according to SRatingsIntel. As per Wednesday, July 26, the company rating was maintained by Morgan Stanley. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by BMO Capital Markets on Thursday, June 1. Raymond James maintained Biogen Inc. (NASDAQ:BIIB) on Tuesday, August 2 with “Strong Buy” rating. The firm has “Buy” rating by SunTrust given on Tuesday, April 24. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, January 25 report. The rating was maintained by Mizuho on Sunday, October 15 with “Hold”. The firm earned “Hold” rating on Thursday, January 25 by Credit Suisse. The stock has “Neutral” rating by Robert W. Baird on Monday, July 27. Jefferies maintained Biogen Inc. (NASDAQ:BIIB) rating on Thursday, January 25. Jefferies has “Hold” rating and $375.0 target. The rating was initiated by Bernstein with “Outperform” on Wednesday, June 29.

Since September 26, 2018, it had 0 insider purchases, and 1 insider sale for $350,000 activity.

Montecito Bank & Trust, which manages about $335.10M US Long portfolio, upped its stake in Cl A by 871 shares to 2,724 shares, valued at $3.29M in 2018Q3, according to the filing. It also increased its holding in Walt Disney Co/The (NYSE:DIS) by 4,064 shares in the quarter, for a total of 13,043 shares, and has risen its stake in Vf Corp (NYSE:VFC).

Investors sentiment decreased to 1.01 in 2018 Q3. Its down 0.01, from 1.02 in 2018Q2. It worsened, as 45 investors sold BIIB shares while 334 reduced holdings. 138 funds opened positions while 243 raised stakes. 167.21 million shares or 1.69% less from 170.10 million shares in 2018Q2 were reported. Adage Prtnrs Group Limited Liability holds 0.2% in Biogen Inc. (NASDAQ:BIIB) or 258,707 shares. Comerica Bancshares, Michigan-based fund reported 41,920 shares. Boston has invested 0.07% in Biogen Inc. (NASDAQ:BIIB). Mufg Americas, New York-based fund reported 5,634 shares. Gotham Asset Ltd Liability reported 79,271 shares or 0.39% of all its holdings. Fosun Ltd accumulated 2,000 shares or 0.03% of the stock. Yhb Investment Advisors invested in 817 shares or 0.04% of the stock. Hanson Mcclain has invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Bryn Mawr Tru Co has 624 shares. California State Teachers Retirement System reported 0.22% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Lombard Odier Asset Management (Switzerland) Sa owns 7,578 shares. Montrusco Bolton Invests accumulated 56,341 shares. Loring Wolcott Coolidge Fiduciary Llp Ma holds 8,373 shares or 0.05% of its portfolio. Paloma Prns Mgmt Co, a Connecticut-based fund reported 110,486 shares. First Fincl Bank Of Omaha has invested 0.4% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Streetinsider.com which released: “Biogen (BIIB) Applauds Quebec Decision to Cover SPINRAZA for broad population of SMA Patients – StreetInsider.com” on December 20, 2018, also Seekingalpha.com with their article: “Biogen teams up with C4 Therapeutics in neurology – Seeking Alpha” published on January 04, 2019, Nasdaq.com published: “Biogen Inks Two Deals to Make Drugs for Neurological Diseases – Nasdaq” on January 07, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Seekingalpha.com and their article: “Biogen commences late-stage study of extended interval dosing for MS med Tysabri – Seeking Alpha” published on January 03, 2019 as well as Seekingalpha.com‘s news article titled: “Quebec to cover Biogen’s SMA med Spinraza – Seeking Alpha” with publication date: December 20, 2018.

More notable recent Independent Bank Corporation (NASDAQ:IBCP) news were published by: Nasdaq.com which released: “Independent Bank Corporation (IBCP) Ex-Dividend Date Scheduled for August 03, 2018 – Nasdaq” on August 02, 2018, also Globenewswire.com with their article: “Independent Bank Corporation Announces Completion of Merger With TCSB Bancorp, Inc. – GlobeNewswire” published on April 02, 2018, Globenewswire.com published: “Independent Bank Corporation Announces Appointment of Terry Beia to Its Board of Directors – GlobeNewswire” on April 24, 2018. More interesting news about Independent Bank Corporation (NASDAQ:IBCP) were released by: Globenewswire.com and their article: “Independent Bank Corporation Announces Shareholder Approval to Acquire Traverse City State Bank – GlobeNewswire” published on March 15, 2018 as well as Globenewswire.com‘s news article titled: “Independent Bank Corporation Announces Date for Its Third Quarter 2018 Earnings Release – GlobeNewswire” with publication date: September 26, 2018.

Since September 6, 2018, it had 2 insider buys, and 2 sales for $295,223 activity. Another trade for 1,573 shares valued at $34,606 was made by Daniel Larry R Jr on Monday, November 5. On Monday, October 29 the insider Ervin Patrick J bought $21,899.

Investors sentiment decreased to 1.52 in 2018 Q3. Its down 0.66, from 2.18 in 2018Q2. It is negative, as 11 investors sold IBCP shares while 33 reduced holdings. 19 funds opened positions while 48 raised stakes. 17.58 million shares or 2.46% more from 17.16 million shares in 2018Q2 were reported. Thrivent For Lutherans invested in 0.01% or 168,447 shares. Wells Fargo Mn invested in 0% or 279,997 shares. Clover Prtn LP reported 138,252 shares. Dupont Mgmt has 46,195 shares for 0.02% of their portfolio. The Ohio-based Meeder Asset Management Inc has invested 0.01% in Independent Bank Corporation (NASDAQ:IBCP). Pub Employees Retirement Of Ohio, Ohio-based fund reported 16,910 shares. Vanguard Grp Inc Inc Inc invested in 0% or 1.01M shares. Pl Capital Limited Co owns 7.1% invested in Independent Bank Corporation (NASDAQ:IBCP) for 1.16 million shares. Thomson Horstmann & Bryant reported 283,954 shares. Moreover, Invesco Limited has 0% invested in Independent Bank Corporation (NASDAQ:IBCP). The Georgia-based Voya Mgmt Limited Liability Company has invested 0% in Independent Bank Corporation (NASDAQ:IBCP). Fmr Ltd Liability owns 90,049 shares or 0% of their US portfolio. Piermont Mgmt invested in 0.45% or 47,690 shares. Ameriprise owns 0% invested in Independent Bank Corporation (NASDAQ:IBCP) for 77,008 shares. California State Teachers Retirement System invested 0% in Independent Bank Corporation (NASDAQ:IBCP).

Independent Bank Corporation (NASDAQ:IBCP) Institutional Positions Chart

Related Posts:

  • No Related Posts

Biogen Inc (BIIB) Shares Sold by BLB&B Advisors LLC

Acadian Asset Management LLC increased its holdings in shares of Biogen by 2,188.6% during the third quarter. Acadian Asset Management LLC …

Biogen logoBLB&B Advisors LLC trimmed its position in Biogen Inc (NASDAQ:BIIB) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,195 shares of the biotechnology company’s stock after selling 178 shares during the quarter. BLB&B Advisors LLC’s holdings in Biogen were worth $360,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of BIIB. National Asset Management Inc. raised its holdings in Biogen by 120.6% in the 3rd quarter. National Asset Management Inc. now owns 1,899 shares of the biotechnology company’s stock valued at $672,000 after acquiring an additional 1,038 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Biogen by 2,188.6% during the third quarter. Acadian Asset Management LLC now owns 122,418 shares of the biotechnology company’s stock worth $43,254,000 after purchasing an additional 117,069 shares during the period. Jackson Square Partners LLC increased its holdings in shares of Biogen by 5.7% during the third quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after purchasing an additional 121,072 shares during the period. Blair William & Co. IL increased its holdings in shares of Biogen by 17.4% during the third quarter. Blair William & Co. IL now owns 18,449 shares of the biotechnology company’s stock worth $6,518,000 after purchasing an additional 2,735 shares during the period. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of Biogen by 13.0% during the third quarter. Rockefeller Capital Management L.P. now owns 321,622 shares of the biotechnology company’s stock worth $113,632,000 after purchasing an additional 37,049 shares during the period. 86.77% of the stock is currently owned by institutional investors.

BIIB has been the topic of several recent research reports. ValuEngine raised shares of Biogen from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. Morgan Stanley raised their target price on shares of Biogen from $394.00 to $401.00 and gave the stock an “overweight” rating in a report on Wednesday, December 19th. JPMorgan Chase & Co. lowered their target price on shares of Biogen from $445.00 to $436.00 and set a “buy” rating on the stock in a report on Wednesday, October 24th. Oppenheimer set a $400.00 target price on shares of Biogen and gave the stock a “buy” rating in a report on Friday, October 19th. Finally, BidaskClub cut shares of Biogen from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. Eight analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $381.86.

Shares of Biogen stock opened at $338.34 on Friday. Biogen Inc has a fifty-two week low of $249.17 and a fifty-two week high of $388.67. The company has a current ratio of 2.75, a quick ratio of 2.46 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $68.01 billion, a price-to-earnings ratio of 15.51, a P/E/G ratio of 1.21 and a beta of 0.99.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, October 23rd. The biotechnology company reported $7.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $6.78 by $0.62. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.33 billion. Biogen had a net margin of 24.08% and a return on equity of 38.70%. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter last year, the firm earned $6.31 earnings per share. Equities analysts anticipate that Biogen Inc will post 25.86 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Biogen Inc (BIIB) Shares Sold by BLB&B Advisors LLC” was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/01/18/biogen-inc-biib-shares-sold-by-blbb-advisors-llc.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Further Reading: How to Invest in an Index Fund

Want to see what other hedge funds are holding BIIB?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Oakbrook Investments LLC Purchases 11635 Shares of Biogen Inc (BIIB)

Acadian Asset Management LLC lifted its position in shares of Biogen by 2,188.6% during the third quarter. Acadian Asset Management LLC now …

Biogen logoOakbrook Investments LLC increased its stake in Biogen Inc (NASDAQ:BIIB) by 23.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,940 shares of the biotechnology company’s stock after acquiring an additional 11,635 shares during the period. Biogen makes up 1.2% of Oakbrook Investments LLC’s investment portfolio, making the stock its 21st largest position. Oakbrook Investments LLC’s holdings in Biogen were worth $18,338,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. National Asset Management Inc. lifted its position in shares of Biogen by 120.6% during the third quarter. National Asset Management Inc. now owns 1,899 shares of the biotechnology company’s stock worth $672,000 after purchasing an additional 1,038 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Biogen by 2,188.6% during the third quarter. Acadian Asset Management LLC now owns 122,418 shares of the biotechnology company’s stock worth $43,254,000 after purchasing an additional 117,069 shares in the last quarter. Jackson Square Partners LLC lifted its position in shares of Biogen by 5.7% during the third quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after purchasing an additional 121,072 shares in the last quarter. Blair William & Co. IL lifted its position in shares of Biogen by 17.4% during the third quarter. Blair William & Co. IL now owns 18,449 shares of the biotechnology company’s stock worth $6,518,000 after purchasing an additional 2,735 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its position in shares of Biogen by 13.0% during the third quarter. Rockefeller Capital Management L.P. now owns 321,622 shares of the biotechnology company’s stock worth $113,632,000 after purchasing an additional 37,049 shares in the last quarter. 86.77% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on BIIB. BidaskClub upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Royal Bank of Canada dropped their price target on shares of Biogen to $338.00 and set a “sector perform” rating for the company in a research note on Monday, November 26th. Oppenheimer dropped their price target on shares of Biogen from $380.00 to $372.00 and set an “outperform” rating for the company in a research note on Tuesday, December 18th. ValuEngine lowered shares of Biogen from a “hold” rating to a “sell” rating in a research note on Wednesday, December 19th. Finally, BTIG Research began coverage on shares of Biogen in a research note on Thursday, December 20th. They issued a “buy” rating and a $362.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Biogen currently has a consensus rating of “Buy” and an average price target of $381.86.

BIIB stock traded up $1.62 during trading on Thursday, hitting $333.65. The company had a trading volume of 5,407 shares, compared to its average volume of 1,276,281. The company has a market capitalization of $68.01 billion, a P/E ratio of 15.28, a PEG ratio of 1.21 and a beta of 0.99. Biogen Inc has a fifty-two week low of $249.17 and a fifty-two week high of $388.67. The company has a quick ratio of 2.46, a current ratio of 2.75 and a debt-to-equity ratio of 0.43.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, October 23rd. The biotechnology company reported $7.40 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.62. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.33 billion. Biogen had a net margin of 24.08% and a return on equity of 38.70%. The company’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.31 earnings per share. Equities analysts anticipate that Biogen Inc will post 25.86 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.fairfieldcurrent.com/news/2019/01/17/oakbrook-investments-llc-purchases-11635-shares-of-biogen-inc-biib.html.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts